This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of AKR-001 in subjects with NASH. The purpose of this research study is to assess how well the different doses of AKR-001 work to reduce the amount of fat in the liver.
|Principal Investigator||Rashmee Patil, MD|
|Sponsor||Akero Therapeutics, Inc|
|Type of Trial||Interventional|